Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1 inhibitor ivosidenib and safety activity in patients with chondrosarcoma.
Jonathan Trent, MD, PhD on Mutant IDH1: Exploring Ivosidenib @JTrentMDPhD @SylvesterCancer
